直接抗病毒药物在丙型肝炎病毒及合并艾滋病病毒感染中的应用进展

在过去几年中，抗丙型肝炎病毒（hepatitis C virus，HCV）治疗药物的研发取得了突破性进展。大量基础和临床研究证实，针对病毒蛋白的直接抗病毒药物（direct-acting antivirals，DAAs）能有效治疗HCV感染，获得高达90%以上的持续病毒应答（sustained viral response，SVR）。然而，由于诸多因素的影响，HCV合并人类免疫缺陷病毒（human immunodeficiency virus，HIV）感染的患者尚未得到有效的抗HCV治疗。在此将重点简述了DAAs的分类、作用机制及其临床试验效果；此外，还介绍了宿主靶向药物（host-targeting agents，HTAs）的研发情况，以及DAAs在HCV合并HIV患者中的临床应用进展。

Research progress on direct-acting antivirals usage for HCV mono-infection and HCV/HIV co-infection

In the past several years, research on the development of new drugs for treatment of hepatitis C virus infection has made a breakthrough. A number of basic and clinical studies have proven that direct-acting antivirals (DAAs) that target specific viral proteins are highly effective in treating HCV with a sustained viral response (SVR) as high as >90%. However, HCV/HIV co-infected individuals have not been able to receive the effective treatment with DAAs due to a number of factors. This paper briefly describes the classification, mechanisms and results of clinical studies on DAAs. In addition, the paper introduces the research on the development of host-targeting agents (HTAs), and treatment of DAAs for HCV/HIV co-infected individuals.